GlassScriptPhysician profile
Joel Patrick Veldhouse
NPI 1659685741
$6,158.40
in general payments reported to CMS, 2019-2025
35 companies · $2,317 in 2025
The $2,317 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.41 · 2021: $14.65 · 2023: $1,528 · 2024: $2,267 · 2025: $2,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,085 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,084.56 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,381.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $838.01 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $639.06 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $482.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $409.00 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $381.63 | 2023-2025 | |
| Exact Sciences Corporation | $272.53 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $200.32 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $184.30 | 2023-2025 | Vraylar, Ubrelvy |
| Esperion Therapeutics, INC. | $159.70 | 2023-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.07 | 2023-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $144.74 | 2023-2024 | Aptiom, Gemtesa |
| Merck Sharp & Dohme LLC | $126.83 | 2024-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Antares Pharma, INC. | $110.87 | 2024-2025 | Xyosted |
| Xeris Pharmaceuticals, INC. | $91.58 | 2023-2024 | Gvoke Hypopen |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $81.95 | 2023-2024 | Yupelri |
| Dexcom, INC. | $77.04 | 2023-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $55.55 | 2024 | Ajovy, Austedo Xr |
| Indivior INC. | $39.81 | 2023 | Sublocade |
| Seqirus USA INC | $37.48 | 2025 | Fluad, Flucelvax |
| Supernus Pharmaceuticals, INC. | $25.30 | 2025 | Qelbree, Xyosted |
| Sanofi Pasteur INC. | $25.15 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $24.03 | 2025 | Rexulti |
| Viatris Specialty LLC | $23.33 | 2025 | Yupelri |
| Ardelyx, INC. | $21.12 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.58 | 2024 | Xifaxan |
| Orexo US, INC. | $20.53 | 2023 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $20.18 | 2025 | Eliquis |
| Hologic Sales and Service, LLC | $18.64 | 2024 | Aptima |
| Abbott Laboratories | $18.56 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.72 | 2023 | Quviviq |
| Halozyme INC | $17.50 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2023 | |
| Cranial Technologies, INC | $14.50 | 2024 | Doc Band |
| Phadia US INC. | $13.83 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Veldhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.